MARKET

CFRX

CFRX

ContraFect
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.36
+0.67
+14.29%
Pre Market: 5.50 +0.14 +2.61% 08:19 04/03 EDT
OPEN
4.650
PREV CLOSE
4.690
HIGH
5.52
LOW
4.550
VOLUME
115.01K
TURNOVER
--
52 WEEK HIGH
13.40
52 WEEK LOW
2.693
MARKET CAP
82.18M
P/E (TTM)
-0.3465
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CFRX stock price target is 17.33 with a high estimate of 22.00 and a low estimate of 15.00.

EPS

CFRX News

More
  • ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference
  • GlobeNewswire · 4d ago
  • CFRX: Interim Futility Analysis for Phase 3 DISRUPT Trial Once 60% Enrolled…
  • Zacks Small Cap Research · 03/23 10:15
  • We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate
  • Simply Wall St. · 03/21 14:01
  • ContraFect Q4 EPS $(1.11) Down From $0.75 YoY
  • Benzinga · 03/18 11:04

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About CFRX

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
More

Webull offers kinds of ContraFect Corp stock information, including NASDAQ:CFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRX stock news, and many more online research tools to help you make informed decisions.